Backed by Sean Harper and Beth Seidenberg, an LA biotech scores a massive $250M crossover ahead of 2022 IPO

Sean Harper

When Acelyrin closed its Series A late last year, it was met with little fanfare. The biotech had only two employees, the former R&D chief and CBO of Horizon Therapeutics, and didn’t even disclose the size of the raise. Westlake Village BioPartners, an LA-based…

...

Click to view original post